Cargando…

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance

SIMPLE SUMMARY: Multiple myeloma (MM) is a common blood cancer that affects plasma cells, a type of immune cell found in bone marrow. Treatment options for MM have improved in recent years, but most patients eventually become resistant to existing therapies, highlighting the need for better treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weir, Philip, Donaldson, David, McMullin, Mary Frances, Crawford, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046772/ https://www.ncbi.nlm.nih.gov/pubmed/36980568 http://dx.doi.org/10.3390/cancers15061682

Ejemplares similares

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Haertle, Larissa, et al.
Publicado: (2023)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
por: Zhang, Hua, et al.
Publicado: (2022)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Adhesion molecules in multiple myeloma oncogenesis and targeted therapy
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma
por: Gutman, Delia, et al.
Publicado: (2009)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Farrell, Mariah L., et al.
Publicado: (2018)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients
por: Weir, Philip, et al.
Publicado: (2022)

Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance
por: Ge, Maolin, et al.
Publicado: (2020)

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
por: Maneix, Laure, et al.
Publicado: (2021)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
por: Haney, Staci L., et al.
Publicado: (2022)

Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors
por: Malek, Ehsan, et al.
Publicado: (2016)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
por: Mitra, A K, et al.
Publicado: (2017)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
por: Mendonca, Nikolai P., et al.
Publicado: (2016)

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
por: Shalem-Cohavi, Naama, et al.
Publicado: (2019)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
por: Chen, John H., et al.
Publicado: (2017)

The Central Role of the Ubiquitin–Proteasome System in EBV-Mediated Oncogenesis
por: Pei, Yonggang, et al.
Publicado: (2022)

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION
por: De Boussac, H., et al.
Publicado: (2022)

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
por: Allmeroth, Kira, et al.
Publicado: (2020)

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2022)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Bennett, Melissa K., et al.
Publicado: (2021)

MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors
por: Cao, Yang-Jia, et al.
Publicado: (2022)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Proteasome inhibitor-induced coronary vasospasm in multiple myeloma: a case report
por: Mikhail, Philopatir, et al.
Publicado: (2021)

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
por: Yu, Zhen, et al.
Publicado: (2022)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
por: Findlay, Steven, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ccrdsum7dgfnlcqlgaug9njfsu